Gut bacteria joins fight against aggressive lung cancer
NCT ID NCT06943235
Summary
This study is testing whether adding probiotics (beneficial bacteria) to a combination of high-dose radiation, chemotherapy, and an immunotherapy drug called adebrelimab can better control limited-stage small cell lung cancer. It will involve 60 patients to see if this approach helps keep the cancer from growing or spreading for longer and is safe. The main goal is to see if patients are cancer-free one year after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.